BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.Stifel 2025 Virtual Immunology and Inflammation Forum – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, Sep ...